Netanya, Israel, January 30, 2024 – Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop therapeutics for cancer patients, announced today the publication of an article featuring its TBX platform technology mechanism of action. The publication was made in the Drug Target Review journal (Vol 10, 2023).
The article, titled “Advancements in Microbiome Engineering Using CRISPR: Unlocking the Potential for Better Medicine”, was authored by Dr. Ziv Lifshitz, Trobix Bio VP R&D. In the article, Dr. Lifshitz describes the various approaches using CRISPR technologies to engineer the microbiome and improve human health. The article describes how Trobix Bio uses the TBX™ platform technology to develop therapeutics that generate a robust and durable therapeutic effect, without disruption of the microbiome structure, and further elucidates the mechanism of action behind the company’s lead products TBX201 and TBX301, currently being developed to treat life-threatening gastrointestinal side effects of leading cancer drugs, Irinotecan, and Immune Checkpoint Inhibitors (ICI), respectively.
Dr. Adi Elkeles, CEO of Trobix Bio, said: “This important publication shines a spotlight on our unique approach to develop microbiome-based therapeutics to meaningfully improve cancer patients’ quality of life and enable improved therapeutic outcomes.”
Trobix Bio (www.trobix.bio) is an Israeli biotech company pioneering the field of human microbiome via its TBX™ platform technology to develop orally administered therapeutics to reduce life-threatening side effects associated with leading oncology therapeutics. The company’s products may enable physicians to complete more oncology treatments at optimal doses while improving cancer patients’ quality of life.
For further information please contact:
Dr. Adi Elkeles
Chief Executive Officer
|Investors & media
+41 79 367 6254